It is considered a research peptide and not approved for general medical use
Nrf2 inhibitor, brusatol in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive cancers by inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 pathways
Using ATP, dephospho-CoA pyrophosphorylase converts 4-phosphopantetheine into 4-dephospho-coenzyme A, releasing pyrophosphate
Indications: resulting either from organic heart disease or from cardiac surgical procedures inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility Contraindications: Patients with idiopathic hypertrophic subaortic stenosis (IHSS) and in patients who have shown previous manifestations of hypersensitivity to dobutamine Patients with IHSS have an asymmetric septal hypertrophy resulting in a dynamic left ventricular outflow obstruction (LVOT)
Reproxalap (Resubmitted NDA), March 16 Aldeyra Therapeutics FDA decision on Reproxalap for the treat of dry eye disease
Liver Detoxification & Toxin Clearance Methionine and choline prevent fatty liver buildup, supporting smoother weight loss trajectories as per recent Nouveau Aesthetics findings